Dyne Therapeutics (NASDAQ:DYN) Trading 5.4% Higher – What’s Next?

Shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) shot up 5.4% on Thursday . The stock traded as high as $11.97 and last traded at $11.87. 871,901 shares traded hands during mid-day trading, a decline of 59% from the average session volume of 2,122,307 shares. The stock had previously closed at $11.26.

Analysts Set New Price Targets

DYN has been the topic of several research analyst reports. Baird R W raised shares of Dyne Therapeutics to a “strong-buy” rating in a research note on Thursday, December 12th. BMO Capital Markets started coverage on shares of Dyne Therapeutics in a research note on Wednesday, March 12th. They set an “outperform” rating and a $50.00 price objective on the stock. Raymond James raised Dyne Therapeutics to a “strong-buy” rating in a report on Thursday, December 12th. Scotiabank began coverage on Dyne Therapeutics in a report on Friday, March 7th. They set a “sector outperform” rating and a $50.00 target price on the stock. Finally, HC Wainwright restated a “buy” rating and set a $46.00 price objective on shares of Dyne Therapeutics in a research report on Monday, March 17th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, twelve have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, Dyne Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.46.

Dyne Therapeutics Stock Up 4.8 %

The firm has a market capitalization of $1.33 billion, a PE ratio of -3.31 and a beta of 1.11. The business’s 50-day moving average price is $13.38 and its 200-day moving average price is $23.75.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Tuesday, March 4th. The company reported ($0.88) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.04. On average, analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current fiscal year.

Insider Activity at Dyne Therapeutics

In related news, insider Oxana Beskrovnaya sold 2,598 shares of the firm’s stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $13.95, for a total transaction of $36,242.10. Following the transaction, the insider now owns 199,087 shares of the company’s stock, valued at approximately $2,777,263.65. This trade represents a 1.29 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Over the last 90 days, insiders sold 6,237 shares of company stock valued at $77,760. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently modified their holdings of the business. Quantbot Technologies LP bought a new position in Dyne Therapeutics in the 3rd quarter worth approximately $34,000. Point72 DIFC Ltd bought a new stake in Dyne Therapeutics in the third quarter valued at about $36,000. GF Fund Management CO. LTD. acquired a new position in Dyne Therapeutics in the fourth quarter worth about $50,000. KBC Group NV lifted its stake in Dyne Therapeutics by 45.3% during the fourth quarter. KBC Group NV now owns 3,135 shares of the company’s stock worth $74,000 after purchasing an additional 978 shares during the period. Finally, Quest Partners LLC grew its stake in shares of Dyne Therapeutics by 898.3% in the 3rd quarter. Quest Partners LLC now owns 3,434 shares of the company’s stock valued at $123,000 after purchasing an additional 3,090 shares during the period. Institutional investors and hedge funds own 96.68% of the company’s stock.

About Dyne Therapeutics

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.